FY2025 EPS Estimates for Verastem Boosted by HC Wainwright

Verastem, Inc. (NASDAQ:VSTM) – Research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Verastem in a research report issued on Thursday, February 5th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings of ($3.19) per share for the year, up from their previous forecast of ($3.21). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q4 2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.66) EPS and FY2027 earnings at ($0.40) EPS.

Several other equities analysts also recently commented on VSTM. Weiss Ratings restated a “sell (d-)” rating on shares of Verastem in a research note on Wednesday, January 21st. Mizuho set a $15.00 price target on Verastem in a report on Wednesday, October 29th. Cantor Fitzgerald upgraded Verastem to a “strong-buy” rating in a research report on Thursday, October 30th. Guggenheim reiterated a “buy” rating on shares of Verastem in a research report on Tuesday, December 30th. Finally, Royal Bank Of Canada set a $13.00 target price on Verastem and gave the stock an “outperform” rating in a research note on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.83.

Verastem Stock Performance

NASDAQ VSTM opened at $6.65 on Monday. The firm’s fifty day moving average price is $7.68 and its two-hundred day moving average price is $8.31. Verastem has a 1 year low of $4.01 and a 1 year high of $11.24. The firm has a market capitalization of $444.09 million, a P/E ratio of -1.65 and a beta of 0.41. The company has a current ratio of 2.58, a quick ratio of 2.55 and a debt-to-equity ratio of 2.06.

Insider Buying and Selling at Verastem

In other news, Director Paul A. Bunn sold 6,250 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $10.00, for a total value of $62,500.00. Following the completion of the sale, the director owned 2,083 shares of the company’s stock, valued at approximately $20,830. This represents a 75.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael Kauffman sold 8,550 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $10.00, for a total value of $85,500.00. Following the completion of the sale, the director owned 8,666 shares in the company, valued at $86,660. The trade was a 49.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 50,478 shares of company stock worth $462,045 in the last three months. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of Verastem

Several hedge funds have recently modified their holdings of VSTM. The Manufacturers Life Insurance Company boosted its holdings in Verastem by 9.8% during the second quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,440 shares during the last quarter. Aries Wealth Management raised its stake in Verastem by 10.5% in the 3rd quarter. Aries Wealth Management now owns 26,249 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 2,500 shares during the period. Russell Investments Group Ltd. raised its position in shares of Verastem by 182.9% in the third quarter. Russell Investments Group Ltd. now owns 4,578 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 2,960 shares during the period. BNP Paribas Financial Markets raised its holdings in Verastem by 110.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,550 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 4,496 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Verastem by 28.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,945 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 6,691 shares in the last quarter. Institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.